STUDY OF NAVELBINE IN COMBINATION WITH CISPLATIN IN TREATMENT OF PATIENTS WITH DISSEMINATED NON‑SMALL CELL LUNG CANCER

The study assessed the efficacy of naavelbine in combination with cisplatin in the first line of treatment of disseminated non-small cell lung cancer (DNCLC). Eighty nine DNCLCpatients(stages III or IV) who have not been exposed to chemotherapy were randomized in to two groups. Group 1 (n = 43) received a combination of navelbine with cisplatin. Group 2 (n = 46) received etoposide with cisplatin. The two groups were comparable in terms of main prognostic indicators. The efficacy of treatment with a navelbine + cisplatin combination (30.2%) proved to be significantly (р < 0.05) higher compared to etoposide + cisplatin (23.2%). Moreover, its toxicity profile was also more beneficial. The median of the time before progression in Group 1 was 5.5 months compared to 4.0 months in Group 2 (р = 0.01). The overall 1-year survival rate was higher in Group 1 (р = 0.18).